Section 2799-C. Reflex sympathetic dystrophy syndrome program

1. There is
  hereby created within the department the  reflex  sympathetic  dystrophy
  syndrome  (RSDS)  program. This program is established to promote public
  awareness of the causes of  RSDS,  the  value  of  early  detection  and
  possible  treatments  thereof,  and  to promote research, via public and
  private sources,  to  accurately  identify,  diagnose,  and  treat  this
  illness.
    2. The department, in developing such program, shall:
    (a)  establish  a  public education and outreach campaign, via written
  materials, brochures, and the internet,  exclusively,  to  promote  RSDS
  education  that  will  enable individuals to make informed choices about
  their health, including but not limited to the following elements:
    (i) cause and nature of the disease;
    (ii) risk factors that contribute to the illness's manifestation;
    (iii) all available treatment options, including benefits and risks of
  those treatment options;
    (iv) environmental safety and injury prevention;
    (v) rest and use of appropriate body mechanics;
    (vi) availability of RSDS diagnostic, treatment, and outreach services
  in the community; and
    (vii) any other factors or elements that might mitigate the effects of
  this disease.
    (b) develop educational materials and  brochures,  exclusively,  which
  shall   be   made  available  to  consumers,  through  state  and  local
  departments  of  health,  hospitals,  clinics,  and  other  health  care
  providers.
    (c) coordinate, promote, and offer professional education programs for
  health  care providers and health-related community based organizations,
  including but not limited to the following:
    (i) research findings;
    (ii) cause and nature of the disease;
    (iii) risk factors, including but not limited to, lifestyle, heredity,
  and drug interactions;
    (iv) diagnostic procedures and appropriate indications for their use;
    (v) all medical and surgical treatment options, including experimental
  and established drug therapies, and  the  benefits  and  risks  of  each
  option;
    (vi) environmental safety and injury prevention; and
    (vii)  availability  of  RSDS  diagnosis  and  treatment  and  support
  services in the community.
    (d) promote research, through both private and public funding  sources
  to accurately identify, diagnose, and treat RSDS.
    3.  The  commissioner  shall  accept and expend any grants, awards, or
  other funds or appropriations as may be made available for the  purposes
  subject  to the limitations as to the approval of expenditures and audit
  as prescribed for state funds by the state finance law.